<p>Introduced in 2019 the Single Anastomosis Sleeve Jejunal (SASJ) Bypass is a bariatric surgery method designed around concepts of reducing gastric volume and enhanced food delivery to the ileum to produce neuroendocrine optimization. SASJ only involves a single anastomosis, does not involve the formation of blind loops, and reserves the possibility of routine endoscopic interventions in the future. This study presents 12-month follow-up data on 158 patients with either obesity II, accompanied by associated medical problems, or obesity III and more severe cases, with or without associated medical problems. The surgery method was chosen based on the surgeon’s interview with each patient, explaining both the investigatory nature of the SASJ procedure (lack of long-term data on outcomes and need for routine long-term monitoring) and its advantages. During the study period, 51 patients agreed to undergo SASJ bypass, while 107 patients underwent Roux-en-Y gastric bypass (RYGB) at the same center. Available Data on 50/51 and 103/107 of patients were analyzed. SASJ achieved 34.5 ± 10.7% TWL and 73.3 ± 22.7% EWL while RYGB resulted in 34.2 ± 6.8% TWL and 80.8 ± 18.7% EWL. Respectively, both the SASJ and RYGB groups experienced significant (<i>P</i> < 0.05) reductions in BMI (47.7 ± 4.7 kg/m² to 31.1 ± 5.1 kg/m² vs. 44.7 ± 5.5 kg/m² to 29.3 ± 4.3 kg/m²), mean weight (128.6 ± 17.1 kg to 83.6 ± 14 kg vs. 118.2 ± 19.2 kg to 77.4 ± 13.0 kg), waist circumference (Δ = 31.0 ± 10.8 cm vs. Δ = 29.0 ± 12.3 cm) and hip circumference (Δ = 25.9 ± 10.6 cm vs. Δ = 25.5 ± 11.5 cm). These outcomes were statistically comparable between the two groups (<i>P</i> > 0.05). With the averages of most measurements falling within normal ranges, both groups showed significant improvements (<i>P</i> < 0.05) in metabolic parameters; fasting blood sugar (FBS) and lipid profiles improved significantly, while liver function tests remained largely unchanged following both.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> <p>Key Points</p> <p>• In a 1-year timeframe, SASJ results in significant BMI reduction and remarkable %TWL and %EWL.</p> <p>• Average measures of FBS, lipid profile, and liver function test elements fall well within normal ranges in the 1-year timeframe following SASJ.</p> <p>• SASJ is followed by marked reductions in waist and hip circumferences.</p> </entry> </row> </tbody> </tgroup> </Table></p>

One-year Weight Loss and Metabolic Outcomes of Single Anastomosis Sleeve Jejunal Bypass: A Retrospective Report with Reference to Roux-en-Y Gastric Bypass

期刊论文
发表日期：

2025年12月15日

查看全文

Nader Moeinvaziri,
Masoud Amini,
Seyed Vahid Hosseini,
Mohammad Ebrahimi,
Babak Hosseini,
Mohammad Sokhanvarian,
Neda Haghighat,
Fardin Karbakhsh Ravari,
Ali Rafiei,
Arash Bagher Pour

摘要

Introduced in 2019 the Single Anastomosis Sleeve Jejunal (SASJ) Bypass is a bariatric surgery method designed around concepts of reducing gastric volume and enhanced food delivery to the ileum to produce neuroendocrine optimization. SASJ only involves a single anastomosis, does not involve the formation of blind loops, and reserves the possibility of routine endoscopic interventions in the future. This study presents 12-month follow-up data on 158 patients with either obesity II, accompanied by associated medical problems, or obesity III and more severe cases, with or without associated medical problems. The surgery method was chosen based on the surgeon’s interview with each patient, explaining both the investigatory nature of the SASJ procedure (lack of long-term data on outcomes and need for routine long-term monitoring) and its advantages. During the study period, 51 patients agreed to undergo SASJ bypass, while 107 patients underwent Roux-en-Y gastric bypass (RYGB) at the same center. Available Data on 50/51 and 103/107 of patients were analyzed. SASJ achieved 34.5 ± 10.7% TWL and 73.3 ± 22.7% EWL while RYGB resulted in 34.2 ± 6.8% TWL and 80.8 ± 18.7% EWL. Respectively, both the SASJ and RYGB groups experienced significant (P < 0.05) reductions in BMI (47.7 ± 4.7 kg/m² to 31.1 ± 5.1 kg/m² vs. 44.7 ± 5.5 kg/m² to 29.3 ± 4.3 kg/m²), mean weight (128.6 ± 17.1 kg to 83.6 ± 14 kg vs. 118.2 ± 19.2 kg to 77.4 ± 13.0 kg), waist circumference (Δ = 31.0 ± 10.8 cm vs. Δ = 29.0 ± 12.3 cm) and hip circumference (Δ = 25.9 ± 10.6 cm vs. Δ = 25.5 ± 11.5 cm). These outcomes were statistically comparable between the two groups (P > 0.05). With the averages of most measurements falling within normal ranges, both groups showed significant improvements (P < 0.05) in metabolic parameters; fasting blood sugar (FBS) and lipid profiles improved significantly, while liver function tests remained largely unchanged following both.

Key Points

• In a 1-year timeframe, SASJ results in significant BMI reduction and remarkable %TWL and %EWL.

• Average measures of FBS, lipid profile, and liver function test elements fall well within normal ranges in the 1-year timeframe following SASJ.

• SASJ is followed by marked reductions in waist and hip circumferences.